In conclusion, in our secondary analyses of a prospectively accrued cohort of HR + patients with early-stage breast cancer treated with an adjuvant AI, patients carrying lysine at OPG rs2073618 had greater risk of treatment-related AIMSS. Here, TNFRSF11B is linked to breast carcinoma.